Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Diamond Biotechnology Co (ROCO:6815) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Diamond Biotechnology Co EBITDA Margin % Related Terms
Diamond Biotechnology Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6815 vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Diamond Biotechnology Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diamond Biotechnology Co EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Diamond Biotechnology Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Diamond Biotechnology Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diamond Biotechnology Co (ROCO:6815) has a EBITDA Margin % of -40.75% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Diamond Biotechnology Co and its competitors. According to the industry distribution chart, Diamond Biotechnology Co ranks #556 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 68.1%.
Is Diamond Biotechnology Co's EBITDA Margin % too high?
Diamond Biotechnology Co's current EBITDA Margin % is -40.75%. Based on the distribution chart, Diamond Biotechnology Co ranks #556 out of 816 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Diamond Biotechnology Co has a GF Score™ of 80/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Diamond Biotechnology Co's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Diamond Biotechnology Co ranks #556 out of 816 companies for EBITDA Margin %. This places Diamond Biotechnology Co in the lower half of its industry. The industry median EBITDA Margin % is 7.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Diamond Biotechnology Co and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diamond Biotechnology Co's current EBITDA Margin % is -40.75%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diamond Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Diamond Biotechnology Co (ROCO:6815) is currently considered Possible Value Trap. The stock's GF Value™ is NT$48.10, compared to a current price of NT$29.70 — trading 38.3% below its estimated fair value. The current EBITDA Margin % is -40.75%. Diamond Biotechnology Co's overall GF Score™ is 80/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Diamond Biotechnology Co (ROCO:6815), the current EBITDA Margin % is -40.75% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diamond Biotechnology Co (ROCO:6815) Overvalued in 2026?
Based on GuruFocus' analysis, Diamond Biotechnology Co stock appears to be undervalued.
The current stock price of NT$29.70 is trading 38.3% below its estimated GF Value™ of NT$48.10.
GuruFocus considers Diamond Biotechnology Co to be Possible Value Trap.
Key valuation signals for ROCO:6815:
EBITDA Margin %: -40.75%
GF Value™: NT$48.10 vs. price of NT$29.70 (38.3% below fair value)
No single metric tells the full story. See the ROCO:6815 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diamond Biotechnology Co Ltd is engaged in the research and development of medical equipment, and medical consumables. It also manufactures and sells medical beauty-level skincare products.
80GF Score
Get the complete analysis for ROCO:6815
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6815 has been successfully added to your 
